Phage Display Technology: Principles, Libraries, and Applications in Drug Discovery

Phage display technology is a molecular screening method in which bacteriophages are engineered to display peptides or proteins on their surfaces while carrying the encoding DNA internally. This direct genotype–phenotype linkage enables the construction of phage display libraries with up to 10¹⁰ variants, allowing high-throughput screening for molecules with desirable binding properties. The concept was pioneered in 1985 by George P. Smith, who demonstrated that foreign peptides could be fused to phage coat proteins and displayed in a heritable fashion.

Since its introduction, phage display has become a cornerstone of molecular discovery, particularly in the fields of antibody engineering, peptide ligand discovery, epitope mapping, and vaccine development. The technology’s ability to generate human therapeutic antibodies has had profound impact, with adalimumab (Humira) standing as a landmark example of a phage display–derived monoclonal antibody approved for clinical use [1,2].

Despite the emergence of other display and library technologies such as mRNA display [3,4] and DNA-encoded libraries (DELs) [5-8], phage display remains highly relevant due to its robustness, scalability, and direct compatibility with therapeutic antibody pipelines. In this review, we examine the principles, methods, and applications of phage display technology, with extended comparisons to mRNA display and DEL platforms.

Several bacteriophage systems are employed in phage display:

• M13 filamentous phage: The most widely used system. The minor coat protein pIII (3–5 copies) is suited for displaying larger proteins such as antibody fragments, while the major coat protein pVIII (~2700–3000 copies) supports high-valency display of short peptides.
• T7 phage: Offers greater robustness and can display larger proteins without requiring secretion through the bacterial membrane.
• T4 phage: Capable of displaying very large proteins and multivalent constructs.
• λ phage: Less common but useful for certain protein formats.

Helper phages and phagemid vectors are often employed in M13 systems. Phagemids carry the display construct, while helper phages provide the structural proteins needed for phage assembly.

The process of phage display screening, also known as biopanning, involves iterative rounds of affinity selection:

1. Library incubation – A large phage display library is exposed to an immobilised target (purified protein, peptide, or even whole cells).
2. Washing – Non-binding phages are washed away under increasingly stringent conditions.
3. Elution – Bound phages are eluted, often by pH shift, enzymatic cleavage, or competitive ligands.
4. Amplification – Eluted phages are amplified in E. coli, regenerating the pool for the next round.
5. Enrichment – After 3–5 rounds, high-affinity binders are enriched and sequenced.

A phage display library is a diverse collection of bacteriophages, each presenting a unique peptide, antibody fragment, or protein variant on its surface. The diversity of a library can reach 10⁹–10¹⁰ unique members, significantly enhancing the probability of identifying rare, high-affinity binders.

• Peptide libraries:
  • Synthetic libraries use randomised oligonucleotides to generate peptides with controlled diversity.
  • Natural libraries use DNA fragments from biological sources.
  • Semi-synthetic libraries combine both strategies.
• Antibody libraries:
  • Naïve libraries are derived from B-cell repertoires of healthy donors, constructed via splice-by-overlap extension PCR, providing broad diversity.
  • Immune libraries originate from immunised donors and typically yield higher-affinity clones against the specific antigen.
  • Synthetic antibody libraries incorporate designed CDR (complementarity-determining region) sequences.
• Fragment formats:
  • scFv (single-chain variable fragments)
  • Fab (fragment antigen-binding)
  • VH and nanobody formats

• Type-3 vectors fuse peptides to all copies of pIII.
• Type-33 vectors allow wild-type and fusion proteins on the same phage.
• Phagemids combined with helper phages enable modular display with controlled copy number.

Phage display technology has broad applications across biomedical research and drug discovery:

Phage display peptide libraries are valuable tools for identifying binding motifs against receptors, enzymes, and protein–protein interaction interfaces. Short peptide ligands discovered via phage display have been used as leads for therapeutics, diagnostics, and targeting agents.

Epitope mapping with phage display identifies the precise binding sites of antibodies on antigens, aiding rational vaccine design and immunodiagnostic assay development.

• Nanobody generation: Selection of VH domains and nanobody scaffolds against membrane proteins.
• Cell-surface selection: Direct screening against intact cells for immuno-oncology targets.
• Diagnostic peptides: For example, HER3P1 peptide has been developed for imaging HER3 expression in tumors.

• Extremely large library sizes (up to ~10¹⁰ variants) 
• Direct genotype–phenotype linkage
• Straightforward amplification in bacteria
• Cost-effective and scalable
• Rapid identification of high-affinity ligands

• Restricted to peptides and proteins (no small-molecule diversity)
• Post-translationally modified proteins are difficult to display
• Large proteins may not fold correctly in the phage context
• cDNA libraries may contain stop codons or non-functional clones

mRNA display is a cell-free in vitro translation system where peptides are covalently linked to their encoding mRNA via puromycin [3]. Key features include:

• Library size: Up to 10¹³ members, surpassing phage libraries.
• Chemical diversity: Incorporation of some non-natural amino acids and macrocyclic scaffolds [4].
• Applications: Particularly suited for targeting protein–protein interaction (PPI) interfaces.

DEL combines combinatorial chemistry with DNA barcoding [5-7]. Features include:

• Library size: 10⁶–10¹² small molecules.
• Chemical diversity: Very high; compatible with drug-like small molecules.
• Screening: Pooled libraries incubated with targets, followed by PCR enrichment and NGS readout [6].
• Applications: Small-molecule discovery, especially for enzymatic targets, PPIs, and molecular glues.
• Integration with AI/ML: Machine learning enhances predictive power and hit triaging [8].

Although this review is centred on phage display, complementary technologies such as DNA-encoded library screening services play a vital role in small-molecule discovery. At Vipergen, we provide custom DEL screening solutions with:

• Modular library design with privileged scaffolds and novel chemotypes
• Screening against challenging targets, including membrane proteins and in intact cells
• Integrated SAR analysis and cheminformatics clustering
• Multiplexed selectivity profiling against target and anti-targets

For researchers pursuing oncology, GPCR ligands, or chemical probes for validation, our DEL screening services provide a high-throughput, scalable platform that complements phage display–based biologics discovery.

Phage display technology remains one of the most influential methods in molecular discovery. By harnessing genotype–phenotype linkage, phage display libraries enable rapid screening of billions of peptides, proteins, and antibody fragments. The method’s impact on antibody therapeutics, peptide discovery, and epitope mapping underscores its continuing relevance, even as complementary technologies such as mRNA display and DEL broaden the molecular space accessible to researchers.

As library construction methods, biopanning strategies, and computational tools evolve, phage display screening will continue to serve as a cornerstone of biologics discovery while integrating seamlessly with next-generation discovery platforms. Its combination of scalability, cost effectiveness, and clinical track record ensures that phage display remains indispensable in the next era of precision drug discovery.

1. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature. 1990;348(6301):552–554. https://doi.org/10.1038/348552a0
2. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol. 1994;12:433–455. https://doi.org/10.1146/annurev.iy.12.040194.002245
3. Roberts RW, Szostak JW. RNA–peptide fusions for the in vitro selection of peptides and proteins. Proc Natl Acad Sci USA. 1997;94(23):12297–12302. https://doi.org/10.1073/pnas.94.23.12297
4. Huang Y, Wiedmann MM, Suga H. RNA Display Methods for the Discovery of Bioactive Macrocycles. Chem Rev. 2019;119(17):10360–10391. https://doi.org/10.1021/acs.chemrev.8b00430
5. Peterson AA, Liu DR. Small-molecule discovery through DNA-encoded libraries. Nat Rev Drug Discov. 2023;22(9):699–722. https://doi.org/10.1038/s41573-023-00713-6
6. Favalli N, Bassi G, Scheuermann J, Neri D. DNA-encoded chemical libraries – achievements and remaining challenges. FEBS Lett. 2018;592(17):2168-2180. https://doi.org/10.1002/1873-3468.13068
7. Mason JW, Wang Y, et al. DNA-encoded library-enabled discovery of proximity-inducing small molecules. Nat Chem Biol. 2024;20:170–179. https://doi.org/10.1038/s41589-023-01458-4
8. McCloskey K, Sigel EA, et al. Machine learning on DNA-encoded libraries: A new paradigm for hit-finding. J Med Chem. 2020;63(16):8857-8866. https://doi.org/10.1021/acs.jmedchem.0c00452